文献速递儿童心血管与肾脏

儿童慢性肾脏病随机试验结局的范围与异质性

Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease.
PubMed 文献 · J Pediatr · 2017-04-24

该研究检索Cochrane肾脏与移植专业注册库至2016年3月,纳入205项涉及各期儿童慢性肾脏病(CKD)的随机试验,提取所有结局域和测量指标。结果显示共报告100个结局域的6158种不同测量,52%为替代结局,38%为临床结局,10%为患者报告结局;血压和复发/缓解报告最多但测量异质性大,死亡率、心血管疾病和生活质量报告较少。结论认为儿童CKD试验结局极异质且以替代结局为主,需促进患者和临床医生重要结局的一致报告。

要点

  • 儿童CKD随机试验报告100个结局域共6158种不同测量,异质性极高。
  • 52%结局域为替代结局,38%为临床结局,10%为患者报告结局。
  • 血压和复发/缓解报告最多,但分别有56和81种不同测量;死亡率、心血管疾病和生活质量报告较少。

核心结论

  • 儿童CKD随机试验报告的结局极异质,且多为替代结局,而非心血管疾病和生活质量等临床和患者中心结局。
  • 确保一致报告对患者和临床医生重要的结局,将提高试验指导临床决策的价值。

研究设计与样本

  • 检索Cochrane肾脏与移植专业注册库至2016年3月,纳入涉及各期儿童CKD的随机试验。
  • 从纳入试验中提取所有结局域和测量指标,评估其频率和特征。
  • 共纳入205项试验;非英文文章被排除。

主要发现

  • 205项试验共报告100个不同结局域的6158种不同测量,每项试验中位报告22个结局域(IQR 13-41)。
  • 52个结局域(52%)为替代结局,38个(38%)为临床结局,10个(10%)为患者报告结局。
  • 最常报告的5个结局域为血压(76项[37%]试验)、复发/缓解(70项[34%])、肾功能(66项[32%])、感染(61项[30%])和身高/青春期发育(51项[25%])。
  • 死亡率(14%)、心血管疾病(4%)和生活质量(1%)报告较少。
  • 报告最多的两个结局血压和复发/缓解分别有56和81种不同结局测量。

临床怎么用

  • 儿科医生解读儿童CKD随机试验时,需注意结局指标以替代结局为主且测量异质,应关注对患者重要的临床结局如心血管疾病和生活质量。
  • 临床决策参考试验证据时,应评估结局指标的一致性和患者相关性,不宜仅依赖替代终点。

局限性

  • 非英文文章被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the range and heterogeneity of outcomes reported in randomized controlled trials of interventions for children with chronic kidney disease (CKD). STUDY DESIGN: The Cochrane Kidney and Transplant Specialized Register was searched to March 2016. Randomized trials involving children across all stages of CKD were selected. All outcome domains and measurements were extracted from included trials. The frequency and characteristics of the outcome domains and measures were evaluated. RESULTS: From 205 trials included, 6158 different measurements of 100 different outcome domains were reported, with a median of 22 domains per trial (IQR 13-41). Overall, 52 domains (52%) were surrogate, 38 (38%) were clinical, and 10 (10%) were patient-reported. The 5 most commonly reported domains were blood pressure (76 [37%] trials), relapse/remission (70 [34%]), kidney function (66 [32%]), infection (61 [30%]), and height/pubertal development (51 [25%]). Mortality (14%), cardiovascular disease (4%), and quality of life (1%) were reported infrequently. The 2 most frequently reported outcomes, blood pressure and relapse/remission, had 56 and 81 different outcome measures, respectively. CONCLUSIONS: The outcomes reported in clinical trials involving children with CKD are extremely heterogeneous and are most often surrogate outcomes, rather than clinical and patient-centered outcomes such as cardiovascular disease and quality of life. Efforts to ensure consistent reporting of outcomes that are important to patients and clinicians will improve the value of trials to guide clinical decision-making. In our study, non-English articles were excluded.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Chong LSH, Sautenet B, Tong A, et al. Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. J Pediatr. 2017. PMID: 28449820. doi:10.1016/j.jpeds.2017.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。